Supernus Pharmaceuticals (SUPN) Goodwill & Intangibles (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Goodwill & Intangibles data on file, last reported at $670.4 million in Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $670.4 million, up 8.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $670.4 million (up 8.28% YoY), and the FY2025 annual result was $694.3 million, up 8.67% from the prior year.
• Goodwill & Intangibles fell to $670.4 million in Q1 2026 per SUPN's latest filing, from $694.3 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $879.5 million in Q1 2022 and troughed at $598.3 million in Q2 2025.
• A 5-year average of $732.1 million and a median of $716.9 million in 2023 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2022 and 2024: Goodwill & Intangibles jumped 101.41% in 2022, then decreased 13.32% in 2024.
• A 5-year view of Goodwill & Intangibles shows it stood at $819.5 million in 2022, then fell by 12.52% to $716.9 million in 2023, then declined by 10.88% to $638.9 million in 2024, then gained by 8.67% to $694.3 million in 2025, then fell by 3.45% to $670.4 million in 2026.
• Business Quant data shows SUPN's Goodwill & Intangibles at $670.4 million in Q1 2026, $694.3 million in Q4 2025, and $742.6 million in Q3 2025.